Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-CD70-ALLO1
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
P-CD70-ALLO1 is an allogeneic CAR-T cell therapy candidate developed by Poseida Therapeutics. It is designed to target CD70, a member of the TNF ligand superfamily that is frequently overexpressed in certain cancers, including acute myeloid leukemia (AML). The therapy uses healthy donor T cells genetically engineered to express a chimeric antigen receptor (CAR) specific for CD70. Preclinical data demonstrate robust anti-leukemic activity with no toxicity to hematopoietic stem cells. The product leverages Poseida’s proprietary technology platform and aims to provide an off-the-shelf cell therapy option for AML and potentially other malignancies expressing CD70[1][2][6].
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on P-CD70-ALLO1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-CD70-ALLO1.